Global mergers and acquisitions activity is accelerating with a force that few anticipated twelve months ago. Morgan Stanley now projects worldwide deal volume will reach a record $6.4 trillion in 2026, underpinned by recovering equity valuations, tighter financing spreads, and renewed corporate confidence. For CFOs, General Counsel, and M&A Directors operating across European and transatlantic markets, the strategic window is opening — but so is the execution risk.

Large Strategic Deals and PE Carve-Outs Define the Current Cycle

Three transactions announced in recent weeks illustrate the dominant forces reshaping the M&A landscape. First, Onsemi agreed to acquire Synaptics in an all-stock deal valued at approximately $7 billion — its largest acquisition to date. The rationale is unambiguous: consolidating AI-enabled device capabilities in the semiconductor sector, where scale and IP depth are becoming decisive competitive differentiators. For deal teams, this signals that technology-driven strategic mergers and acquisitions are no longer confined to software; hardware integration is back at the centre of corporate finance conversations.

Second, H.B. Fuller announced the acquisition of UK-based Advanced Medical Solutions Group for approximately £715 million, including debt. This cross-border deal combines a US specialty chemicals platform with a European medtech innovator — a structure that reflects the broader consolidation logic in healthcare materials, where regulatory harmonisation between the UK post-Brexit framework and EU MDR creates both complexity and opportunity for acquirers with the right compliance infrastructure.

Third, Reuters reported early-stage takeover interest in Qiagen from private equity sponsors EQT, Advent, and KKR, with indicative bids reportedly starting at $50 per share. Qiagen’s diagnostics platform — defensible revenues, recurring consumables, and global distribution — represents precisely the type of asset that sponsors are targeting in the current cycle: predictable cash flows with room for operational improvement and eventual re-listing or strategic exit.

Cross-Border Complexity: Regulatory and Structural Considerations

For European deal teams, the resurgence of cross-border deals brings a familiar set of structural challenges that require early-stage planning rather than reactive remediation.

  • Foreign Direct Investment screening: The EU FDI Regulation (2019/452), now fully operational across member states, requires acquirers — particularly those with non-EU ultimate ownership — to map screening obligations before signing. In the UK, the National Security and Investment Act 2021 adds a parallel mandatory notification regime for 17 sensitive sectors, including semiconductors and medical devices.
  • Antitrust sequencing: Large-cap cross-border deals increasingly face multi-jurisdictional merger control filings. The European Commission’s revised merger guidelines and the UK CMA’s post-Brexit assertiveness mean that deal timelines must account for substantive review periods of six to eighteen months in complex cases.
  • Due diligence depth: In a higher-rate, higher-scrutiny environment, financial due diligence must extend beyond EBITDA normalisation to include ESG compliance, data governance under GDPR, and supply chain resilience — all of which affect post-merger integration planning and, ultimately, valuation.

Private equity sponsors re-engaging with European life sciences — as evidenced by the reported Qiagen process — must also navigate the interplay between leveraged buyout financing structures and the European Central Bank’s evolving guidance on leveraged lending, which continues to constrain debt multiples for certain transaction profiles.

Implications for Decision-Makers: Building Readiness Before the Window Narrows

The current macro backdrop — stronger equity markets, stabilising interest rates, and renewed corporate confidence — is historically conducive to accelerated deal activity. However, the gap between announced and closed transactions remains wide for those unprepared for execution complexity.

Board members and executive teams should consider the following priorities:

  • Refresh your M&A readiness framework now, before competitive processes intensify. This includes pre-clearing FDI and antitrust exposure maps for priority target geographies.
  • Stress-test post-merger integration assumptions against current inflation, talent retention, and technology migration costs — not 2021 benchmarks.
  • Engage corporate finance advisers early on capital structure optionality, particularly if all-stock structures (as in the Onsemi-Synaptics deal) become more prevalent as a mechanism to manage valuation gaps.
  • Assess venture capital and minority stake positions in your portfolio for strategic exit or consolidation opportunities before the next valuation reset.

Key takeaway: The data points to a sustained, broad-based recovery in global mergers and acquisitions, with European cross-border deals and private equity take-privates leading the next wave. Decision-makers who invest in structural readiness — regulatory mapping, due diligence capability, and integration planning — today will be positioned to move decisively when the right opportunity emerges. Those who wait for certainty will find themselves competing in a crowded, expensive process.